{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:41Z","timestamp":1791689561340,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bone.2019.06.011","type":"journal-article","created":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T09:33:26Z","timestamp":1560677606000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta"],"prefix":"10.1016","volume":"127","author":[{"given":"Lu-jiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di-chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-bo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10028","key":"10.1016\/j.bone.2019.06.011_bb0005","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2019.06.011_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bone.2019.06.011_bb0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.matbio.2018.03.010","article-title":"Osteogenesis imperfecta and therapeutics","volume":"71\u201372","author":"Morello","year":"2018","journal-title":"Matrix Biol."},{"issue":"12","key":"10.1016\/j.bone.2019.06.011_bb0020","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"27","author":"Trejo","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2019.06.011_bb0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.21037\/jss.2017.10.01","article-title":"The genetic implication of scoliosis in osteogenesis imperfecta: a review","volume":"3","author":"Liu","year":"2017","journal-title":"J. Spine Surg."},{"issue":"12","key":"10.1016\/j.bone.2019.06.011_bb0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/jbmr.2895","article-title":"Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study","volume":"31","author":"Folkestad","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2019.06.011_bb0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5435\/JAAOS-D-15-00169","article-title":"The spine in patients with osteogenesis imperfecta","volume":"25","author":"Wallace","year":"2017","journal-title":"J. Am. Acad. Orthop. Surg."},{"issue":"9902","key":"10.1016\/j.bone.2019.06.011_bb0040","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bone.2019.06.011_bb0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/archdischild-2017-313234","article-title":"Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis","volume":"103","author":"Saraff","year":"2018","journal-title":"Arch. Dis. Child."},{"issue":"5","key":"10.1016\/j.bone.2019.06.011_bb0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000331128","article-title":"Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta","volume":"76","author":"Semler","year":"2011","journal-title":"Horm. Res. Paediatr."},{"issue":"4","key":"10.1016\/j.bone.2019.06.011_bb0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2019.06.011_bb0060","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2019.06.011_bb0065","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2019.06.011_bb0070","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/S0149-2918(03)80327-2","article-title":"Zoledronic acid: a new parenteral bisphosphonate","volume":"25","author":"Li","year":"2003","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.bone.2019.06.011_bb0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4158\/EP171910.OR","article-title":"Zoledronic acid versus alendronate in the treatment of children with osteogenesis imperfecta: a 2-year clinical study","volume":"24","author":"Lv","year":"2018","journal-title":"Endocr. Pract."},{"issue":"3","key":"10.1016\/j.bone.2019.06.011_bb0080","first-page":"137","article-title":"Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry","volume":"61","author":"Sumnik","year":"2004","journal-title":"Horm. Res."},{"issue":"3","key":"10.1016\/j.bone.2019.06.011_bb0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jbspin.2008.07.017","article-title":"Radiographic methods for evaluating osteoporotic vertebral fractures","volume":"76","author":"Grados","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"47","key":"10.1016\/j.bone.2019.06.011_bb0090","first-page":"487","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"7","author":"Li","year":"2009","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"12","key":"10.1016\/j.bone.2019.06.011_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082098","article-title":"Bone mineral density of the spine in 11,898 Chinese infants and young children: a cross-sectional study","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bone.2019.06.011_bb0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00774-006-0737-5","article-title":"Establishment of peak bone mineral density in Southern Chinese males and its comparisons with other males from different regions of China","volume":"25","author":"Tan","year":"2007","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2019.06.011_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bone.2016.02.018","article-title":"Scoliosis in osteogenesis imperfecta caused by COL1A1\/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment","volume":"86","author":"Sato","year":"2016","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2019.06.011_bb0110","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00198-018-4448-2","article-title":"Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X","volume":"29","author":"Song","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2019.06.011_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00223-002-2101-7","article-title":"The interaction between Sillence type and BMD in osteogenesis imperfecta","volume":"73","author":"Kok","year":"2003","journal-title":"Calcif. Tissue Int."},{"issue":"9","key":"10.1016\/j.bone.2019.06.011_bb0120","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00198-017-4094-0","article-title":"A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid","volume":"28","author":"Lv","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2019.06.011_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res. Paediatr."},{"issue":"5","key":"10.1016\/j.bone.2019.06.011_bb0130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2019.06.011_bb0135","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2019.06.011_bb0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1442-200X.2008.02649.x","article-title":"Growth of infants with osteogenesis imperfecta treated with bisphosphonate","volume":"51","author":"Hasegawa","year":"2009","journal-title":"Pediatr. Int."},{"issue":"6","key":"10.1016\/j.bone.2019.06.011_bb0145","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2019.06.011_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00223-008-9211-9","article-title":"Intravenous pamidronate in osteogenesis imperfecta type VII","volume":"84","author":"Cheung","year":"2009","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2019.06.011_bb0155","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bone.2019.06.011_bb0160","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00198-017-4141-x","article-title":"Long-term follow-up in osteogenesis imperfecta type VI","volume":"28","author":"Trejo","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2019.06.011_bb0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000351374","article-title":"Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age","volume":"79","author":"Alcausin","year":"2013","journal-title":"Horm. Res. Paediatr."},{"issue":"19","key":"10.1016\/j.bone.2019.06.011_bb0170","first-page":"3049","article-title":"Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta","volume":"124","author":"Li","year":"2011","journal-title":"Chin. Med. J."},{"issue":"12","key":"10.1016\/j.bone.2019.06.011_bb0175","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4158\/EP161322.OR","article-title":"Effects of long-term alendronate treatment on a large sample of pediatric patients with osteogenesis imperfecta","volume":"22","author":"Lv","year":"2016","journal-title":"Endocr. Pract."},{"issue":"7","key":"10.1016\/j.bone.2019.06.011_bb0180","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2019.06.011_bb0185","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1651-2227.2003.tb00577.x","article-title":"Treatment of children with osteogenesis imperfecta in Estonia","volume":"92","author":"Maasalu","year":"2003","journal-title":"Acta Paediatr."},{"issue":"9419","key":"10.1016\/j.bone.2019.06.011_bb0190","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.bone.2019.06.011_bb0195","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/ajmg.a.32508","article-title":"Popcorn calcification in osteogenesis imperfecta: incidence, progression, and molecular correlation","volume":"146A","author":"Obafemi","year":"2008","journal-title":"Am. J. Med. Genet. A"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219302431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328219302431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:45:24Z","timestamp":1757612724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328219302431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":39,"alternative-id":["S8756328219302431"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2019.06.011","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2019.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}